NIAID researchers used structural information about two malaria parasite proteins along with mechanistic information about the interaction between them to design and build an entirely novel candidate vaccine. When tested in rats, their “structure-based design 1” (SBD1) immunogen vaccine performed better than other experimental malaria vaccines. It also upends the conventional wisdom that successful vaccines must elicit receptor-blocking antibodies.
In children with cerebral malaria, brain swelling can cause seizures, coma, and death. Researchers from NIAID and their colleagues studied children with cerebral malaria in Malawi to better understand the underlying causes of these devastating symptoms.
HPAI Influenza Devastating Birds, Marine Mammals in Peru--Study Identifies Concerning Viral Mutations
NIAID-funded researchers working in Peru have signaled concern about the deaths of birds and marine mammals from highly pathogenic avian influenza (HPAI) that has been spreading globally.
With ticks expanding their territories in many parts of the world, a NIAID research group has likewise expanded its promising vaccine research to two typically rare pathogens with potential for public health importance -- Kyasanur Forest disease and Alkhurma hemorrhagic fever.
Syphilis, a common sexually transmitted infection (STI) caused by the bacteria Treponema pallidum, can result in adult neurological and organ damage, as well as congenital abnormalities, stillbirths, and neonatal deaths. More research is urgently needed to diversify the diagnostic, preventive, and therapeutic options available to alter the course of the public health threat of syphilis. NIAID supports research to address these areas including studies featured at the recent STI & HIV World Congress in Chicago.
SARS-CoV-2 evolves three times faster in white-tailed deer than in people, making NIAID-funded scientists at The Ohio State University and colleagues ask whether deer are an important reservoir for emerging virus variants.
A new NIAID-funded study shows how inconsistent malaria control measures in East Africa could be aiding the emergence of drug-resistant mutations in the primary parasite that causes malaria.
World Mosquito Day 2023—How Mathematical Modeling Reveals the Link Between Climate Change and Mosquito-Borne Diseases
As global temperatures rise, it has become more urgent to understand the interactions between climate, mosquitoes, and the pathogens mosquitoes transmit to humans. NIAID Now spoke to Luis Chaves, Ph.D., a 2023 Scholar with the National Institutes of Health (NIH) Climate Change and Health Initiative, about his work about the impacts of environmental change on the ecology of insect vectors and the diseases they transmit.
On this World Photo Day, we explore colorized microscopy images with NIAID microscopist John Bernbaum and visual specialist Julie Marquardt.
NIAID researchers used mice to investigate a possible relationship between parasitic worm infection and resistance to severe COVID-19.
A team of vaccine production experts from South Africa recently finished training with NIAID Vaccine Research Center scientists. Their objective: to globally produce vaccines against a list of troubling infectious diseases.
Study Examines the Association of Frailty, Age, and Biological Sex with COVID-19 Vaccine–Induced Immunity in Older Adults
Older adults were disproportionately affected during the COVID-19 pandemic, and while many vaccine clinical trials included older adults, they failed to include those who were particularly old or frail. Immunosenescence, or the process of declining immune function with age, greatly affects susceptibility to infections. Evidence suggests that the effects of aging on the immune system differs...
Viral hepatitis is an inflammatory liver disease caused by infection with any of the known hepatitis viruses—A, B, C, D, and E. Most of the global viral hepatitis burden is from hepatitis B and C, which affect 354 million people and result in 1.1 million deaths annually. The Centers for Disease Control and Prevention estimates that in 2020 there were 14,000 and 50,300 new acute infections of...
As the International AIDS Society’s 12th Conference on HIV Science (IAS 2023) conference drew to a close on Wednesday, HIV.gov continued our conversations about the latest research being presented, with updates on post-exposure prophylaxis for STIs (Doxy-PEP), implementation of HIV PrEP, and the effectiveness of U=U.
This blog is cross-posted from HIV.gov.
On Tuesday at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), HIV.gov continued our conversations about research highlights, including a focus on the latest about HIV vaccines. We also heard an update from the NIH Office of AIDS Research.
NIH’s Carl Dieffenbach, Ph.D., Director of the Division of AIDS at the National...
The International AIDS Society’s 12th Conference on HIV Science (IAS 2023) opened Sunday, with thousands of scientists, policy leaders, and advocates gathered to present and discuss the latest advances in HIV research. HIV.gov’s coverage of the conference began with two video conversations looking ahead to the exciting research that will be presented.
IAS Conference Highlights—Heart Disease Prevention for People with HIV, Long-acting HIV Prevention and Treatment
During the first full day of sessions at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), HIV.gov shared conversations on important study findings about reducing cardiovascular disease among people with HIV and the latest developments with long-acting prevention and treatment options that could one day become safe and effective alternatives to daily oral pills.
SARS-CoV-2 may have both immediate and long-term symptoms associated with infection. According to the Center for Disease Control and Prevention, 7.5% of U.S. adults develop post-acute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. PASC is characterized by varying symptoms, including fatigue, shortness of breath, heart palpitations or chest pain, brain fog, insomnia, dizziness...
Recurrent urinary tract infections (rUTI) affect people all around the world and contribute greatly to morbidity, especially for females. In the United States, over one million women seek medical care for rUTIs each year, which are most commonly caused by uropathogenic Escherichia coli (E. coli) and treated with antibiotics. While history of a prior UTI is a significant risk factor, other drivers...
Do you know some people who almost never get sick and bounce back quickly when they do, while other people frequently suffer from one illness or another? NIAID-supported researchers have pinpointed an attribute of the immune system called immune resilience that helps explain why some people live longer and healthier lives than others.
NIAID scientists and colleagues are one step closer to developing a safe and effective therapy against alphaviruses, which are spread by mosquitoes and can cause two types of disease in people: causing severe neurological impairment such as encephalitis (brain swelling) or crippling muscle pain similar to arthritis.
Mpox has been present in west, central and east Africa for decades, with the first human case identified in 1970. In May 2022, a global mpox outbreak caused by a specific strain of the virus (referred to as “clade IIb”) was the first epidemiologic evidence of community mpox transmission outside of the historically affected African regions. More than 80,000 cases and 140 mpox-related deaths have...
Register now to take part in an important conversation about National HIV Vaccine Awareness Day—an annual observation to recognize the many community members, health professionals, and scientists working together to develop a vaccine to prevent HIV. The HIV.gov-hosted Live with Leadership conversation will take place on Thursday, May 18, from 2:30–3:00pm ET.
Developing a universal influenza vaccine is a significant priority for NIAID scientists. Two new studies describe a unique candidate developed by NIAID's Vaccine Research Center that performed well in a Phase 1 clinical trial.
The study found that infants who were not infected with RSV in the first year of life had a 26% lower risk of asthma at 5 years of age than those who were infected with RSV as infants.